Published in Medical Letter on the CDC and FDA, July 29th, 2007
Featuring a unique delivery format, Clindesse(TM) is expected to be the only one-time treatment for bacterial vaginosis that will be available in China following registration of Clindesse(TM) with the Chinese State Food and Drug Administration (SFDA). Under the terms of the agreement, Beijing Med-Pharm will complete late stage clinical development and registration of Clindesse(TM) with the SFDA prior...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.